WILEX AG / Research Update 17.06.2010 08:41 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. --------------------------------------------------------------------------- WILEX successfully completed Phase I study with the MEK inhibitor WX-554 Munich, Germany, 17 June 2010. WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock Exchange) successfully completed a Phase I dose escalation study with the MEK inhibitor WX-554 demonstrating for the first time WX-554 activity in humans. The trial aimed to determine safety, tolerance and the optimal biological dose for the inhibition of the MEK system by WX-554. The study, which was conducted in Germany, tested five increasing dose levels, each administered once by a 15 min infusion of WX-554 in five healthy male volunteers. In addition to safety and tolerance, the pharmacokinetic and pharmacodynamic properties of the MEK inhibitor were also investigated. The substance was safe and well tolerated in the 25 healthy volunteers. The MEK signal transduction pathway was inhibited in a dose-dependent matter reaching complete inhibition at 1 mg/kg body weight. Dr. Paul Bevan, Head of Research and Development and member of the Executive Management Board of WILEX AG, commented: 'We are delighted with the positive results of WX-554 in this study. With it we have a further product in our clinical pipeline which, due to its mechanism of action, could be used in many oncological indications. We will now initiate the further development of this promising agent with the clinical testing of an oral formulation.' About WX-554 The orally available, small-molecule MEK inhibitor is one of five oncology preclinical programmes obtained under the strategic alliance agreed with UCB in January 2009. Mitogen activated protein kinase (MEK) has been shown to play a central role in signal transduction. MEK has been linked to a multitude of biological processes such as cell division, cell differentiation and cell death. The MEK signalling pathway is over expressed in more than 30% of cancers, resulting in uncontrolled cell growth and proliferation. About WILEX AG WILEX AG is a biopharmaceutical company based in Munich and is listed at the Frankfurt Stock Exchange at the Regulated Market / Prime Standard. WILEX's mission is to develop drugs with a low side effect profile and targeted treatment of different types of cancer as well as diagnostic agents for specific detection of tumours. The Company's product candidates are based on antibodies and small molecules. WILEX has an attractive product pipeline which includes both drug and diagnostic candidates: A pivotal Phase III study with REDECTANE(R) has been completed and positive data published. RENCAREX(R) is undergoing a Phase III registration trial. Positive MESUPRON(R) Phase II data in the indication pancreatic cancer have been published and another Phase II trial in breast cancer is ongoing. A further oncology project (PI3K inhibitor WX-037) is in preclinical development and three antibody programmes are in research. WILEX aims within a few years to be able to finance its research and development programmes from its operating cash flow. Website: http://www.WILEX.com, ISIN DE0006614720 / WKN 661472 / Symbol WL6 Contact WILEX AG Corporate Communications Katja Arnold (CIRO) Grillparzerstr. 10 81675 Munich, Germany Tel.: +49 (0)89-41 31 38-126 Fax: +49 (0)89-41 31 38-99 Mobile: +49 (0)160-93 60 30 22 Email: investors@wilex.com This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as 'estimates', 'believes', 'expects', 'may', 'will' 'should' 'future', 'potential' or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments. 17.06.2010 08:41 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv at |[![CDATA[|[a href="http://www.dgap-medientreff.de"|]www.dgap-medientreff.de|[/a|]]]|] and |[![CDATA[|[a href="http://www.dgap.de"|]www.dgap.de|[/a|]]]|] --------------------------------------------------------------------------- Language: English Company: WILEX AG Grillparzerstr. 10 81675 München Deutschland Phone: +49 (0)89 41 31 38 - 0 Fax: +49 (0)89 41 31 38 - 99 E-mail: info@wilex.com Internet: www.wilex.com ISIN: DE0006614720 WKN: 661472 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------
DGAP-News: WILEX AG: WILEX successfully completed Phase I study with the MEK inhibitor WX-554
| Source: EQS Group AG